关键信息
-
基因名
IGFBP-3
- 应用
-
别名
BP53; IBP3; Growth Hormone-Dependent Binding Protein; Acid Stable Subunit Of The 140 K IGF Complex
-
种属
Mouse
-
表达系统
HEK293
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P47878
-
表达区间
Ser152~Gln292
-
蛋白长度
Partial
-
分子量
17kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) is a crucial regulator of the insulin-like growth factor (IGF) signaling pathway, playing an essential role in cellular growth, differentiation, and apoptosis. Elevated levels of IGFBP-3 have been associated with various physiological and pathological conditions, including cancer, metabolic disorders, and aging. Research on recombinant IGFBP-3 has gained prominence due to its potential therapeutic applications, particularly in cancer treatment, where it has been shown to inhibit tumor growth by modulating the availability of IGFs and inducing apoptosis in malignant cells. Additionally, IGFBP-3 exhibits anti-inflammatory properties, making it a candidate for addressing metabolic diseases and cardiovascular issues. The ability to produce IGFBP-3 as a recombinant protein allows for the exploration of its biological functions and mechanisms of action in a controlled manner, facilitating the development of IGFBP-3-based therapies. Recent studies have focused on optimizing the expression systems for recombinant IGFBP-3, enhancing its stability and bioactivity, and understanding its interactions with other molecular pathways. As the body of research on IGFBP-3 continues to expand, it underscores the importance of this protein as a key player in cellular regulation and its potential as a therapeutic target in various diseases.
